COMMUNIQUÉS West-GlobeNewswire

Tvardi Therapeutics Selects Ulcerative Colitis as Initial Indication for TTI-109
30/07/2026
STAT3 acts as a convergent node downstream of multiple signaling pathways implicated in ulcerative colitis (UC), integrating immune dysregulation, inflammation and tissue remodeling More than 70% of patients do not [...]
PharmAla Issues Q3 Financial Statements and AGM Update
30/07/2026
TORONTO, July 30, 2026 (GLOBE NEWSWIRE) -- PharmAla Biotech Holdings Inc. (“ PharmAla ” or the “ Company ”) (CSE: MDMA) (OTC: MDXXF), a biotechnology company focused on the research, development, and manufacturing of [...]
InflaRx to Report Second Quarter 2026 Results on August 6, 2026
30/07/2026
Jena, Germany, July 30, 2026 (GLOBE NEWSWIRE) -- InflaRx N.V. (Nasdaq: IFRX), a biopharmaceutical company pioneering anti-inflammatory therapeutics by targeting the complement system, today announced that the Company [...]
Palvella Therapeutics Chief Scientific Officer Jeff Martini, Ph.D. Selected to Present at Upcoming FDA Public Workshop on Drug Repurposing
30/07/2026
Hybrid public meeting on August 5th will explore approaches to selecting and prioritizing promising FDA-approved drugs for repurposing, with the potential to accelerate patient access to effective therapies for [...]
Alterity Therapeutics Releases Appendix 4C – Q4 FY26 Quarterly Cash Flow Report & Corporate Update
30/07/2026
Highlights FDA End-of-Phase 2 (EOP2) meeting minutes confirmed a registrational pathway for ATH434 in Multiple System Atrophy (MSA) FDA agreed that a single pivotal Phase 3 trial plus confirmatory evidence could support [...]
Atavistik Bio Partners with Cure HHT Clinical Trial Network to Advance Development of ATV-1601 for Hereditary Hemorrhagic Telangiectasia
30/07/2026
Partnership with Cure HHT strengthens patient engagement and supports streamlined clinical trial execution Harmony-HHT Phase 1/2 trial activates first clinical site at Massachusetts General Hospital, marking an [...]
INmune Bio Establishes Scientific Advisory Board to Support Late-Stage Development and Expansion of CORDStrom™ Platform
30/07/2026
Global Experts in MSC Clinical Translation to Advise Ebstrocel™ Regulatory and Clinical Development and Guide Expansion of CORDStrom Product Opportunities BOCA RATON, Fla., July 30, 2026 (GLOBE NEWSWIRE) -- INmune Bio [...]
Glow Peptide Stack Launched by Kylo Peptides for Laboratory Use
30/07/2026
Sheridan, Wyoming , July 30, 2026 (GLOBE NEWSWIRE) -- Kylo Peptides has announced that it has added the GLOW peptide stack to its research catalog. The product supplies three separately sealed, lyophilized vials of the [...]
20/20 BioLabs to Host Investor Webinar on August 5, 2026, to Discuss Commercial Opportunities Following Management’s Recent East Asia Business Development Tour
30/07/2026
Chief Executive Officer Jonathan Cohen to Discuss BIO Asia-Taiwan Participation and Strategic Meetings in Taipei, Tokyo, and Seoul Webinar to Be Held Wednesday, August 5, 2026 at 12:00 p.m. Eastern Time; Registration Is [...]
Lexicon Pharmaceuticals to Report Second Quarter 2026 Financial Results on August 6, 2026
30/07/2026
THE WOODLANDS, Texas, July 30, 2026 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced the Company will release its second quarter 2026 financial results on Thursday, August 6, 2026, prior [...]
Lite Strategy Repurchases 13% of Outstanding Shares Since December, Increasing Litecoin Backing Per Share
30/07/2026
Lite Strategy Buys Back Roughly 4.9 Million Shares at an Average Price of $1.11 with No Debt Incurred SAN DIEGO, July 30, 2026 (GLOBE NEWSWIRE) -- Lite Strategy, Inc. (Nasdaq: LITS) (“Lite Strategy” or the “Company”), [...]
Cingulate Announces Publication of Phase 3 ADHD Trial Results in Journal of Child and Adolescent Psychopharmacology
30/07/2026
Publication helps establish the efficacy and safety profile of of CTx-1301, reinforcing the potential of Cingulate’s Precision Timed Release™ platform technology KANSAS CITY, Kan., July 30, 2026 (GLOBE NEWSWIRE) -- [...]
Disc Medicine Reports Second Quarter 2026 Financial Results and Provides Business Update
30/07/2026
Completed Type A meeting with the FDA on bitopertin and aligned that the Phase 3 APOLLO study, if successful, can serve as the basis for CRL response; topline data expected in Q4 2026 Launched Expanded Access Program ( [...]
Newly FDA-Approved REVTORPYK™ (gedatolisib) Included in the National Comprehensive Cancer Network® (NCCN®) Clinical Practice Guidelines for HR+/HER2- Locally Advanced or Metastatic Breast Cancer
30/07/2026
REVTORPYK (gedatolisib) in combination with fulvestrant, with or without palbociclib, listed as a preferred Category 1 regimen for second-line or subsequent treatment for tumors without a PIK3CA mutation following [...]
Relation unveils MORGAN, the next-generation model of cellular biology
30/07/2026
LONDON, July 30, 2026 (GLOBE NEWSWIRE) -- Relation today announced MORGAN (Multi-Omic Regulatory Genomics using Artificial Neural Networks), our flagship cellular foundation model designed to transform how new biology [...]
Actimed Therapeutics Strengthens Board with Appointment of Dr. Anders Ullman
30/07/2026
London, UK – 30 July 2026. Actimed Therapeutics Ltd (“Actimed”), a UK based clinical stage specialty pharmaceutical company focused on bringing innovation to the treatment of cancer cachexia and other muscle wasting [...]
Relation Announces Expanded Collaboration with GSK
30/07/2026
Up to $110 million upfront and success-based milestones collaboration will generate large-scale human cellular perturbation datasets to advance understanding of disease biology LONDON, July 30, 2026 (GLOBE NEWSWIRE) -- [...]
AB2 Bio receives $30 million from Nippon Shinyaku for exclusive U.S. commercialization rights to Tadekinig Alfa
30/07/2026
AB2 Bio receives $30 million from Nippon Shinyaku for exclusive U.S. commercialization rights to Tadekinig Alfa Nippon Shinyaku exercises its exclusive U.S. commercialization option for Tadekinig alfa after AB2 Bio’s [...]
Curium advances plans for second investment in Romania to expand access to advanced nuclear medicine
30/07/2026
Proposed expansion in the Cluj-Napoca region intended to strengthen PET imaging supply and support continued development of regional nuclear medicine services BOSTON, July 30, 2026 (GLOBE NEWSWIRE) -- Curium™ announced [...]

Pages